Resiliency of lung cancers to EGFR inhibitor treatment unveiled, offering opportunities to divide and conquer EGFR inhibitor resistance. [electronic resource]
Producer: 20130308Description: 872-5 p. digitalISSN:- 2159-8290
- Cell Line, Tumor
- Class I Phosphatidylinositol 3-Kinases
- Drug Resistance, Neoplasm -- genetics
- ErbB Receptors -- antagonists & inhibitors
- Erlotinib Hydrochloride
- Gefitinib
- Humans
- Lung Neoplasms -- drug therapy
- Molecular Targeted Therapy
- Mutation
- Phosphatidylinositol 3-Kinases -- genetics
- Protein Kinase Inhibitors -- pharmacology
- Quinazolines -- therapeutic use
- Receptor, ErbB-2 -- biosynthesis
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.